Valuation: Lonza Group AG

Capitalization 33.73B 43.39B 36.86B 31.84B 59.39B 4,098B 59.92B 400B 156B 1,968B 163B 159B 6,795B P/E ratio 2026 *
29.3x
P/E ratio 2027 * 24x
Enterprise value 36.9B 47.46B 40.32B 34.83B 64.97B 4,482B 65.54B 438B 171B 2,153B 178B 174B 7,433B EV / Sales 2026 *
5.17x
EV / Sales 2027 * 4.59x
Free-Float
99.36%
Yield 2026 *
1.11%
Yield 2027 * 1.27%
1 day-0.66%
1 week+0.79%
Current month+0.79%
1 month-4.58%
3 months-6.36%
6 months-8.94%
Current year-10.19%
1 week 471.6
Extreme 471.6
502
1 month 470.1
Extreme 470.1
544.2
Current year 454.6
Extreme 454.6
585.6
1 year 454.6
Extreme 454.6
594.8
3 years 308.6
Extreme 308.6
616
5 years 308.6
Extreme 308.6
785.4
10 years 152.8
Extreme 152.8
785.4
Manager TitleAgeSince
Chief Executive Officer 54 2024-06-30
Director of Finance/CFO 54 2021-11-30
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 65 2014-04-15
Director/Board Member 68 2014-04-15
Director/Board Member 66 2016-04-25
Change 5d. change 1-year change 3-years change Capi.($)
-0.66%+0.79%-17.41%-14.33% 43.39B
-1.54%+6.21%+34.54%+27.04% 34.7B
-0.49%+1.67%+250.84%+462.96% 30.15B
+0.04%+13.27%+19.95%-3.92% 29.83B
-2.02%-1.05%+30.59%+26.11% 28.46B
-3.04%+8.03% - - 14.74B
-6.96%+0.55%+203.99%+4,495.82% 14.48B
-0.41%+0.57%+134.69%+112.07% 12.51B
-0.64%+0.54%+5.32%-4.75% 12.29B
-1.10%+1.55%+43.23%+106.90% 12.11B
Average -1.68%+3.21%+78.42%+578.66% 23.27B
Weighted average by Cap. -1.40%+3.55%+67.46%+379.21%

Financials

2026 *2027 *
Net sales 7.14B 9.19B 7.8B 6.74B 12.58B 868B 12.69B 84.73B 33.03B 417B 34.46B 33.74B 1,439B 8B 10.29B 8.74B 7.55B 14.09B 972B 14.21B 94.93B 37.01B 467B 38.61B 37.8B 1,612B
Net income 1.16B 1.49B 1.27B 1.09B 2.04B 141B 2.06B 13.76B 5.36B 67.67B 5.6B 5.48B 234B 1.4B 1.8B 1.53B 1.32B 2.46B 170B 2.48B 16.58B 6.46B 81.56B 6.74B 6.6B 282B
Net Debt 3.17B 4.07B 3.46B 2.99B 5.58B 385B 5.62B 37.57B 14.64B 185B 15.28B 14.96B 638B 2.98B 3.84B 3.26B 2.82B 5.25B 362B 5.3B 35.39B 13.79B 174B 14.39B 14.09B 601B
Logo Lonza Group AG
Lonza Group AG is one of the world leaders of the contract development and manufacturing of pharmaceutical and biotechnology products. Net sales break down by family of products and services as follows: - biologics and bio-pharmaceuticals (55.9%): microbiological fermentation products, mammalian cell-based bio-pharmaceuticals, monoclonal antibodies, therapeutic proteins, etc.; - synthesis products (24.7%): chemopharmaceutical products, bioconjugates, small molecules, active pharmaceutical ingredients, complex intermediates, etc.; - specialised therapeutic products (15.8%): cell and gene therapies, synthetic therapeutic nucleic acids, oligonucleotides, microbial biological products, etc.; - others (3.6%).
Employees
20,000
Date Price Change Volume
26-05-08 483.00 CHF -0.66% 234,734
26-05-07 486.20 CHF -1.50% 187,116
26-05-06 493.60 CHF +0.69% 173,738
26-05-05 490.20 CHF +2.30% 217,626
26-05-04 479.20 CHF 0.00% 213,020
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
483.00CHF
Average target price
673.61CHF
Spread / Average Target
+39.46%

Quarterly revenue - Rate of surprise